BC Week In Review | Nov 22, 2016
Clinical News

Cogenzia: Ph III COACT-1 and COACT-2 data

Top-line data from the identical, double-blind, international Phase III COACT-1 and COACT-2 trials in a total of 1,136 patients with moderate to severe diabetic foot infections showed that up to 4 daily applications of 32.5...
BioCentury | Oct 3, 2016
Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
BC Week In Review | Jul 11, 2016
Clinical News

CollaRx gentamicin topical: Completed Phase III enrollment

Innocoll completed enrollment of about 500 patients in the double-blind, placebo-controlled, international Phase III COACT-2 trial of Cogenzia given for 28 days. Innocoll Holdings plc (NASDAQ:INNL), Athlone, Ireland   Product: CollaRx gentamicin topical , Cogenzia ( INL-002...
BC Week In Review | Jul 11, 2016
Clinical News

CollaRx gentamicin topical: Completed Phase III enrollment

Innocoll completed enrollment of about 500 patients in the double-blind, placebo-controlled, U.S. Phase III COACT-1 trial of Cogenzia given for 28 days. Innocoll Holdings plc (NASDAQ:INNL), Athlone, Ireland   Product: CollaRx gentamicin topical , Cogenzia ( INL-002...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
BC Week In Review | Aug 10, 2015
Clinical News

CollaRx gentamicin topical regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) to Cogenzia from Innocoll as an adjunctive treatment of moderate and severe diabetic foot infections. The topical bioresorbable collagen sponge with gentamicin sulfate is in Phase III testing...
BC Week In Review | Jun 22, 2015
Clinical News

CollaRx gentamicin topical: Phase III started

Innocoll began the double-blind, placebo-controlled, international Phase III COACT-2 trial of Cogenzia given for 28 days in about 500 patients. Patients will receive systemic antibiotic therapy plus Cogenzia, a placebo sponge or no sponge. Innocoll...
BC Week In Review | May 25, 2015
Clinical News

Cogenzia gentamicin topical: Phase III started

Innocoll began the double-blind, U.S. Phase III COACT-1 trial of Cogenzia given for 28 days in about 500 patients. Patients will receive systemic antibiotic therapy plus Cogenzia, a placebo sponge or no sponge. The identical...
BioCentury | Jul 28, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.79 to $167.04 last week after EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a...
BC Extra | Jul 25, 2014
Financial News

Ocular, Innocoll take haircuts to get out IPO door

Ocular Therapeutix Inc. (NASDAQ:OCUL) and Innocoll GmbH (NASDAQ:INNL) priced IPOs on Friday. Ocular raised $65 million through the sale of 5 million shares at $13. The price values the company at $267.4 million. Earlier this...
Items per page:
1 - 10 of 18